Nardi V - Search Results

1

ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.

Nardi V, Naveiras O, Azam M, Daley GQ. Nardi V, et al. Blood. 2009 Apr 16;113(16):3813-20. doi: 10.1182/blood-2008-07-167189. Epub 2009 Jan 26. Blood. 2009. PMID: 19171873 Free PMC article.

2

Response to "Expanding the Clinicopathologic Spectrum of YAP1-MAML2-Rearranged Thymic Neoplasm".

Vivero M, Davineni P, Nardi V, Chan JKC, Sholl LM. Vivero M, et al. Among authors: nardi v. Mod Pathol. 2023 Mar;36(3):100090. doi: 10.1016/j.modpat.2022.100090. Epub 2023 Feb 15. Mod Pathol. 2023. PMID: 36788097 Free article. No abstract available.

3

SPOT/Dx Pilot Reanalysis and College of American Pathologists Proficiency Testing for KRAS and NRAS Demonstrate Excellent Laboratory Performance.

Zehir A, Nardi V, Konnick EQ, Lockwood CM, Long TA, Sidiropoulos N, Souers RJ, Vasalos P, Lindeman NI, Moncur JT. Zehir A, et al. Among authors: nardi v. Arch Pathol Lab Med. 2024 Feb 1;148(2):139-148. doi: 10.5858/arpa.2023-0322-CP. Arch Pathol Lab Med. 2024. PMID: 37776255 Free article.

4

A screen to identify drug resistant variants to target-directed anti-cancer agents.

Azam M, Raz T, Nardi V, Opitz SL, Daley GQ. Azam M, et al. Among authors: nardi v. Biol Proced Online. 2003;5:204-210. doi: 10.1251/bpo63. Epub 2003 Oct 24. Biol Proced Online. 2003. PMID: 14615817 Free PMC article.

5

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

Nardi V, Azam M, Daley GQ. Nardi V, et al. Curr Opin Hematol. 2004 Jan;11(1):35-43. doi: 10.1097/00062752-200401000-00006. Curr Opin Hematol. 2004. PMID: 14676625 Review.

6

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.

Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Azam M, et al. Among authors: nardi v. Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9244-9. doi: 10.1073/pnas.0600001103. Epub 2006 Jun 5. Proc Natl Acad Sci U S A. 2006. PMID: 16754879 Free PMC article.

7

Farnesyl transferase inhibitor resistance probed by target mutagenesis.

Raz T, Nardi V, Azam M, Cortes J, Daley GQ. Raz T, et al. Among authors: nardi v. Blood. 2007 Sep 15;110(6):2102-9. doi: 10.1182/blood-2006-12-064907. Epub 2007 May 29. Blood. 2007. PMID: 17536018 Free PMC article.

8

Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.

Nardi V, Raz T, Cao X, Wu CJ, Stone RM, Cortes J, Deininger MW, Church G, Zhu J, Daley GQ. Nardi V, et al. Oncogene. 2008 Jan 31;27(6):775-82. doi: 10.1038/sj.onc.1210698. Epub 2007 Aug 6. Oncogene. 2008. PMID: 17684485

9

FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.

Le Y, Xu L, Lu J, Fang J, Nardi V, Chai L, Silberstein LE. Le Y, et al. Among authors: nardi v. Am J Hematol. 2009 May;84(5):273-8. doi: 10.1002/ajh.21381. Am J Hematol. 2009. PMID: 19358301 Free article.

10

Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment.

Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Naveiras O, et al. Among authors: nardi v. Nature. 2009 Jul 9;460(7252):259-63. doi: 10.1038/nature08099. Epub 2009 Jun 10. Nature. 2009. PMID: 19516257 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

187 results

Search Page

Filters